apg 115 treatment Search Results


apg 115 treatment  (MedChemExpress)
93
MedChemExpress apg 115 treatment
<t>APG-115</t> <t>exhibits</t> therapeutic effects on TC both in vitro and in vivo. (A) CCK-8 assay demonstrating the relative cell viability of TPC-1 and B-CPAP cells at different concentrations of APG-115. (B) Cell scratch assay of B-CPAP and TPC-1 cells treated with APG-115 at 0 and 24 h. Scar bar = 100 μM. (C) Photograph of the tumors from the control and APG-115 treatment groups. (D,E) Tumor volume and weight of the mice from the control and APG-115 treatment groups. * p < 0.05 versus control group. Data are expressed as mean ± SEM, n = 5.
Apg 115 Treatment, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apg 115 treatment/product/MedChemExpress
Average 93 stars, based on 1 article reviews
apg 115 treatment - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
mdm2 inhibitor apg-115  (Ascentage Pharma)
90
Ascentage Pharma mdm2 inhibitor apg-115
Simplified timeline of the milestone discoveries of <t>MDM2</t> and its inhibitors.
Mdm2 Inhibitor Apg 115, supplied by Ascentage Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mdm2 inhibitor apg-115/product/Ascentage Pharma
Average 90 stars, based on 1 article reviews
mdm2 inhibitor apg-115 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


APG-115 exhibits therapeutic effects on TC both in vitro and in vivo. (A) CCK-8 assay demonstrating the relative cell viability of TPC-1 and B-CPAP cells at different concentrations of APG-115. (B) Cell scratch assay of B-CPAP and TPC-1 cells treated with APG-115 at 0 and 24 h. Scar bar = 100 μM. (C) Photograph of the tumors from the control and APG-115 treatment groups. (D,E) Tumor volume and weight of the mice from the control and APG-115 treatment groups. * p < 0.05 versus control group. Data are expressed as mean ± SEM, n = 5.

Journal: ACS Omega

Article Title: APG-115 Induces SLC7A11-Mediated Ferroptosis and Upregulates PD-L1 Expression in Thyroid Cancer

doi: 10.1021/acsomega.5c04710

Figure Lengend Snippet: APG-115 exhibits therapeutic effects on TC both in vitro and in vivo. (A) CCK-8 assay demonstrating the relative cell viability of TPC-1 and B-CPAP cells at different concentrations of APG-115. (B) Cell scratch assay of B-CPAP and TPC-1 cells treated with APG-115 at 0 and 24 h. Scar bar = 100 μM. (C) Photograph of the tumors from the control and APG-115 treatment groups. (D,E) Tumor volume and weight of the mice from the control and APG-115 treatment groups. * p < 0.05 versus control group. Data are expressed as mean ± SEM, n = 5.

Article Snippet: We measured the cell viability of TC cell lines B-CPAP and TPC-1 following APG-115 treatment using a CCK-8 kit (HY-K0301, MCE).

Techniques: In Vitro, In Vivo, CCK-8 Assay, Wound Healing Assay, Control

APG-115 inhibits the growth of TC patient-derived organoids. (A) Images of TC patient-derived organoids after APG-115 treatment. Scale bar = 100 μM. (B) Concentration–response viability curves of organoids following APG-115 treatment for 5 days. (C) IC 50 values of TC-derived organoids in APG-115 treatment.

Journal: ACS Omega

Article Title: APG-115 Induces SLC7A11-Mediated Ferroptosis and Upregulates PD-L1 Expression in Thyroid Cancer

doi: 10.1021/acsomega.5c04710

Figure Lengend Snippet: APG-115 inhibits the growth of TC patient-derived organoids. (A) Images of TC patient-derived organoids after APG-115 treatment. Scale bar = 100 μM. (B) Concentration–response viability curves of organoids following APG-115 treatment for 5 days. (C) IC 50 values of TC-derived organoids in APG-115 treatment.

Article Snippet: We measured the cell viability of TC cell lines B-CPAP and TPC-1 following APG-115 treatment using a CCK-8 kit (HY-K0301, MCE).

Techniques: Derivative Assay, Concentration Assay

APG-115 treatment upregulates the expression levels of PD-L1, p53, and MDM2 in TC cells. (A) WB assay detected the proteins of PD-L1, p53, and MDM2 in TPC-1 and B-CPAP cells after treatment with APG-115 at 0.125, 0.25, 0.5, 1.0, and 2.0 μM. (B)­Relative expression levels of MDM2, PD-L1, and p53 proteins in BCPAP and TPC-1 cells. ns = nonsignificant, * p < 0.05, ** p < 0.01, *** p < 0.001 versus control group. Data are expressed as mean ± SEM, n = 3. (C) Immunohistochemical staining of the PD-L1 and MDM2 from the tissues of control and APG-115-treated groups. Scale bar = 20 μM. (D) Percentage of immunohistochemically positive area of MDM2 and PD-L1 in mouse tissues from control and APG-115-treated groups. * p < 0.05, *** p < 0.001 versus control group. Data are expressed as mean ± SEM, n = 3. (E) Flow cytometry analysis demonstrating the PD-L1 expression levels in TPC-1 cells from control and APG-115 treatment groups. (F) Correlation analysis of PD-L1 expression level and the p53 pathway in TC.

Journal: ACS Omega

Article Title: APG-115 Induces SLC7A11-Mediated Ferroptosis and Upregulates PD-L1 Expression in Thyroid Cancer

doi: 10.1021/acsomega.5c04710

Figure Lengend Snippet: APG-115 treatment upregulates the expression levels of PD-L1, p53, and MDM2 in TC cells. (A) WB assay detected the proteins of PD-L1, p53, and MDM2 in TPC-1 and B-CPAP cells after treatment with APG-115 at 0.125, 0.25, 0.5, 1.0, and 2.0 μM. (B)­Relative expression levels of MDM2, PD-L1, and p53 proteins in BCPAP and TPC-1 cells. ns = nonsignificant, * p < 0.05, ** p < 0.01, *** p < 0.001 versus control group. Data are expressed as mean ± SEM, n = 3. (C) Immunohistochemical staining of the PD-L1 and MDM2 from the tissues of control and APG-115-treated groups. Scale bar = 20 μM. (D) Percentage of immunohistochemically positive area of MDM2 and PD-L1 in mouse tissues from control and APG-115-treated groups. * p < 0.05, *** p < 0.001 versus control group. Data are expressed as mean ± SEM, n = 3. (E) Flow cytometry analysis demonstrating the PD-L1 expression levels in TPC-1 cells from control and APG-115 treatment groups. (F) Correlation analysis of PD-L1 expression level and the p53 pathway in TC.

Article Snippet: We measured the cell viability of TC cell lines B-CPAP and TPC-1 following APG-115 treatment using a CCK-8 kit (HY-K0301, MCE).

Techniques: Expressing, Control, Immunohistochemical staining, Staining, Flow Cytometry

(A) Images of TPC-1 and B-CPAP cells after APG-115 treatment at different concentrations detected by the C11-BODIPY581/591 probe. Scale bar = 100 μM. (B,C) WB assay demonstrated the proteins of SLC7A11 and GPX4 levels following APG-115 treatment in TPC-1 and B-CPAP cells; Relative expression levels of SLC7A11 and GPX4 proteins in BCPAP and TPC-1 cells following APG-115 treatment. ns = nonsignificant, * p < 0.05, ** p < 0.01, *** p < 0.001 versus control group. Data are expressed as mean ± SEM, n = 3. (D) Images of TPC-1 and B-CPAP cells in control, APG-115, FER-1, and combined treatment groups were detected by the C11-BODIPY581/591 probe. Scale bar = 100 μM. (E) WB assay and the relative expression levels of SLC7A11 and PD-L1 proteins in control, APG-115, FER-1, and combined treatment groups, both in TPC-1 and B-CPAP cells. ns = nonsignificant, * p < 0.05, ** p < 0.01, *** p < 0.001. Data are expressed as mean ± SEM, n = 3.

Journal: ACS Omega

Article Title: APG-115 Induces SLC7A11-Mediated Ferroptosis and Upregulates PD-L1 Expression in Thyroid Cancer

doi: 10.1021/acsomega.5c04710

Figure Lengend Snippet: (A) Images of TPC-1 and B-CPAP cells after APG-115 treatment at different concentrations detected by the C11-BODIPY581/591 probe. Scale bar = 100 μM. (B,C) WB assay demonstrated the proteins of SLC7A11 and GPX4 levels following APG-115 treatment in TPC-1 and B-CPAP cells; Relative expression levels of SLC7A11 and GPX4 proteins in BCPAP and TPC-1 cells following APG-115 treatment. ns = nonsignificant, * p < 0.05, ** p < 0.01, *** p < 0.001 versus control group. Data are expressed as mean ± SEM, n = 3. (D) Images of TPC-1 and B-CPAP cells in control, APG-115, FER-1, and combined treatment groups were detected by the C11-BODIPY581/591 probe. Scale bar = 100 μM. (E) WB assay and the relative expression levels of SLC7A11 and PD-L1 proteins in control, APG-115, FER-1, and combined treatment groups, both in TPC-1 and B-CPAP cells. ns = nonsignificant, * p < 0.05, ** p < 0.01, *** p < 0.001. Data are expressed as mean ± SEM, n = 3.

Article Snippet: We measured the cell viability of TC cell lines B-CPAP and TPC-1 following APG-115 treatment using a CCK-8 kit (HY-K0301, MCE).

Techniques: Expressing, Control

Simplified timeline of the milestone discoveries of MDM2 and its inhibitors.

Journal: Pharmacological Reviews

Article Title: MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

doi: 10.1124/pharmrev.123.001026

Figure Lengend Snippet: Simplified timeline of the milestone discoveries of MDM2 and its inhibitors.

Article Snippet: Only one phase I trial of single-dose treatment has been completed for an oral MDM2 inhibitor APG-115 (Ascentage Pharma) in patients with advanced solid tumors or lymphoma (NCT02935907) to determine the MTD, DLTs, and recommended dose for a future phase II trial.

Techniques:

Selected examples of completed clinical trials of MDM2 inhibitors

Journal: Pharmacological Reviews

Article Title: MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

doi: 10.1124/pharmrev.123.001026

Figure Lengend Snippet: Selected examples of completed clinical trials of MDM2 inhibitors

Article Snippet: Only one phase I trial of single-dose treatment has been completed for an oral MDM2 inhibitor APG-115 (Ascentage Pharma) in patients with advanced solid tumors or lymphoma (NCT02935907) to determine the MTD, DLTs, and recommended dose for a future phase II trial.

Techniques:

Selected clinical trials ongoing or currently recruiting patients

Journal: Pharmacological Reviews

Article Title: MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

doi: 10.1124/pharmrev.123.001026

Figure Lengend Snippet: Selected clinical trials ongoing or currently recruiting patients

Article Snippet: Only one phase I trial of single-dose treatment has been completed for an oral MDM2 inhibitor APG-115 (Ascentage Pharma) in patients with advanced solid tumors or lymphoma (NCT02935907) to determine the MTD, DLTs, and recommended dose for a future phase II trial.

Techniques: Mutagenesis, Activity Assay, Amplification, Transplantation Assay

Representative examples highlighting the role of MDM2 in drug resistance. MDM2-p53 feedback loop regulates MGMT expression to promote temozolomide resistance. MDM2/AKT/AR signaling enhances the EMT to increase the resistance to chemotherapy. MDM2 associates with stem cell markers CD133 and CD34 in maintaining the stemness properties of cancer cells, contributing to the chemotherapy resistance. Increased NF- κ B transcriptional activity is involved in Aurora-A-promoted gefitinib resistance. MDM2 negatively regulates NFAT1. The combination of MDM2 inhibitors and ICIs may overcome the resistance of patients to immunotherapy by activating cytotoxic T cells and blocking the immune checkpoint. AKT, protein kinase B; AR, androgen receptor; CD133, prominin-1; MGMT, O-6-methylguanine-DNA methyltransferase.

Journal: Pharmacological Reviews

Article Title: MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

doi: 10.1124/pharmrev.123.001026

Figure Lengend Snippet: Representative examples highlighting the role of MDM2 in drug resistance. MDM2-p53 feedback loop regulates MGMT expression to promote temozolomide resistance. MDM2/AKT/AR signaling enhances the EMT to increase the resistance to chemotherapy. MDM2 associates with stem cell markers CD133 and CD34 in maintaining the stemness properties of cancer cells, contributing to the chemotherapy resistance. Increased NF- κ B transcriptional activity is involved in Aurora-A-promoted gefitinib resistance. MDM2 negatively regulates NFAT1. The combination of MDM2 inhibitors and ICIs may overcome the resistance of patients to immunotherapy by activating cytotoxic T cells and blocking the immune checkpoint. AKT, protein kinase B; AR, androgen receptor; CD133, prominin-1; MGMT, O-6-methylguanine-DNA methyltransferase.

Article Snippet: Only one phase I trial of single-dose treatment has been completed for an oral MDM2 inhibitor APG-115 (Ascentage Pharma) in patients with advanced solid tumors or lymphoma (NCT02935907) to determine the MTD, DLTs, and recommended dose for a future phase II trial.

Techniques: Expressing, Activity Assay, Blocking Assay

Structures of representative MDM2 inhibitors. (A) Peptide inhibitors. (B) Representative single-ring inhibitors. (C) Representative bicyclic inhibitors. (D) Others.

Journal: Pharmacological Reviews

Article Title: MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

doi: 10.1124/pharmrev.123.001026

Figure Lengend Snippet: Structures of representative MDM2 inhibitors. (A) Peptide inhibitors. (B) Representative single-ring inhibitors. (C) Representative bicyclic inhibitors. (D) Others.

Article Snippet: Only one phase I trial of single-dose treatment has been completed for an oral MDM2 inhibitor APG-115 (Ascentage Pharma) in patients with advanced solid tumors or lymphoma (NCT02935907) to determine the MTD, DLTs, and recommended dose for a future phase II trial.

Techniques:

Structures of representative PROTAC MDM2 inhibitors.

Journal: Pharmacological Reviews

Article Title: MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future

doi: 10.1124/pharmrev.123.001026

Figure Lengend Snippet: Structures of representative PROTAC MDM2 inhibitors.

Article Snippet: Only one phase I trial of single-dose treatment has been completed for an oral MDM2 inhibitor APG-115 (Ascentage Pharma) in patients with advanced solid tumors or lymphoma (NCT02935907) to determine the MTD, DLTs, and recommended dose for a future phase II trial.

Techniques: